Mereo BioPharma Group plc (MREO) Stock

Healthcare · Biotechnology · Member of Other US Stocks

Mereo BioPharma Group plc (MREO) closed at USD 0.31 on 2026-10-14, a change of -85.2 % over the past year, with a market capitalization of USD 49.36M.

Mereo BioPharma Group plc recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

Mereo BioPharma Group plc key figures

Previous close

USD 0.31 (2026-10-14)

1-year change

-85.2 %

Market cap

USD 49.36M

Enterprise value

USD 20.27M

P/E ratio (trailing)

-1.63

P/E ratio (forward)

-13.48

EPS (trailing)

-0.19

EPS (forward)

-0.02

PEG ratio

n/a

Price to book

1.72

Revenue growth

n/a

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

1.42

Employees

39

Analyst consensus (third-party)

buy

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About Mereo BioPharma Group plc

Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of rare diseases in the United Kingdom and the United States. The company develops Setrusumab, an antibody for the treatment of osteogenesis imperfecta; Alvelestat, an oral small molecule that is in Phase II clinical trial to treat Alpha-1 anti-trypsin deficiency associated lung disease; and Vantictumab, an anti-FZD monoclonal antibody for the treatment of autosomal dominant osteopetrosis type 2. It also develops Leflutrozole, an oral aromatase inhibitor, which is in Phase 2 trials for use in the treatment of hypogonadotropic hypogonadism; Navicixizumab, which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Etigilimab, an IgG1 monoclonal antibody which binds to the human TIGIT receptor on immune cells for the Treatment of advanced solid tumors; and Acumapimod, a p38 MAP kinase inhibitor that is in Phase II clinical trials to treat acute exacerbations of chronic obstructive pulmonary disease. The company has a license agreement with Feng Biosciences for the development and commercialization of navicixizumab; license agreement with ReproNovo for the development and commercialization of leflutrozole; and licensing agreement with AstraZeneca. Mereo BioPharma Group plc was incorporated in 2015 and is headquartered in London, United Kingdom.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for Mereo BioPharma Group plc and compare it with other stocks.